Hemolytic-uremic syndrome: Difference between revisions
No edit summary |
|||
| Line 41: | Line 41: | ||
==Treatment== | ==Treatment== | ||
[[Hemolytic-uremic syndrome medical therapy|Medical Therapy]] | [[Hemolytic-uremic syndrome surgery|Surgery]] | [[Hemolytic-uremic syndrome Prevention|Prevention]] | [[Hemolytic-uremic syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hemolytic-uremic syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Hemolytic-uremic syndrome medical therapy|Medical Therapy]] | [[Hemolytic-uremic syndrome surgery|Surgery]] | [[Hemolytic-uremic syndrome Primary prevention|Primary Prevention]] | [[Hemolytic-uremic syndrome secondary prevention|Secondary Prevention]] |[[Hemolytic-uremic syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hemolytic-uremic syndrome future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | ==Case Studies== | ||
[[Hemolytic-uremic syndrome case study one|Case #1]] | [[Hemolytic-uremic syndrome case study one|Case #1]] | ||
Revision as of 13:53, 26 July 2018
For patient information click here
| Hemolytic-uremic syndrome | |
| ICD-10 | D59.3 |
|---|---|
| ICD-9 | 283.11 |
| OMIM | 235400 |
| DiseasesDB | 13052 |
| MedlinePlus | 000510 |
| MeSH | D006463 |
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Synonyms and keywords: Haemolytic-uraemic syndrome; HUS
Overview
Historical Perspective
Classification
Pathophysiology
- shiga toxin–induced
endothelial cytotoxicity in the hemolytic uremic syndrome after infection with shiga toxin–producing Escherichia coli or other microorganisms. Thrombotic microangiopathy can also occur in patients with pneumococcal sepsis and less commonly other infections in which microbial neuraminidases expose the Thomsen-Friedenreich antigen on endothelial and red cells, subjecting the cells to attack by preexisting antibodies against the antigen
Causes
Differentiating Hemolytic-uremic syndrome from other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention |Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related chapters
de:Hämolytisch-urämisches Syndrom no:Hemolytisk-uremisk syndrom nn:Hemolytisk uremisk syndrom sr:Хемолитички уремијски синдром